This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Tuesday's Health Winners & Losers

Shares of CollaGenex Pharmaceuticals (CGPI) were among the best-performing health-related stocks Tuesday, jumping 11% after the company said the Food and Drug Administration approved its oral treatment for rosacea.

The company's Oracea pill will be the first FDA-approved oral treatment for the skin condition. "Oracea is the first of a series of dermatology products we have in development, and we are very pleased that our NDA was approved by the FDA within 10 months of submission," the company said. CollaGenex said that the drug will be ready for distribution in July. CollaGenex shares were trading at $13.01, up $1.33.

Vical (VICL - Get Report) rose 4% after the company announced a collaborative agreement with AnGes, a Japanese biopharmaceutical firm, to develop Vical's Allovectin-7 cancer treatment. As part of the agreement, AnGes will provide up to $100 million in clinical trial funding and make milestone payments that are tied to sales targets. Through cash and equity investments totaling nearly $23 million, AnGes will fund a Phase III trial of Allovectin-7, which will be conducted in the U.S. AnGes will also pay royalties to Vical that are tied to product sales in specified Asian countries. AnGes will have exclusive marketing rights to Allovectin-7 in the specified Asian countries, while Vical will retain marketing rights in the rest of the world. Vical shares were up 27 cents to $6.35.

Applera (ABI) fell 2% after the company's Applied Biosystems unit said it plans to acquire privately held Agencourt Personal Genomics for about $120 million in cash. The transaction, which is expected to close during the third quarter, will cut fiscal 2007 and 2008 earnings, Applied Biosystems said. During fiscal 2009, however, the deal is expected to be accretive. "After conducting a thorough evaluation of more than 40 companies and academic research groups, we have concluded that APG's technology is both tested and commercializable," Applied Biosystems said in a press release. Shares of Applied Biosystems were recently trading down 55 cents to $29.31. Shares of Beckman Coulter (BEC), which owns a minority interest in Agencourt, were up 9 cents to $55.42.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs